DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6tps3s/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H2 2013" report to their offering.
'Anthrax - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax.
Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources
- A snapshot of the global therapeutic scenario for Anthrax.
- A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anthrax pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Key Topics Covered:
Pipeline Products for Anthrax - Overview
Pipeline Products for Anthrax - Comparative Analysis
Anthrax - Therapeutics under Development by Companies
Anthrax - Therapeutics under Investigation by Universities/Institutes
Anthrax - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Anthrax - Products under Development by Companies
Anthrax - Products under Investigation by Universities/Institutes
Anthrax - Companies Involved in Therapeutics Development
Anthrax - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Therapeutic Class
Anthrivig - Drug Profile
NP-015 - Drug Profile
AV-7909 - Drug Profile
GC-1109 - Drug Profile
PreviThrax - Drug Profile
Recombinant Anthrax Vaccine - Drug Profile
MDX-1303 - Drug Profile
AVP-21D9 - Drug Profile
ETI-204 - Drug Profile
Anthrax Vaccine - Drug Profile
ARD-1100 - Drug Profile
MVA-BN Anthrax - Drug Profile
MU-1140 - Drug Profile
EV-021 - Drug Profile
oritavancin disphosphate - Drug Profile
CST-102 - Drug Profile
PMX-30016 - Drug Profile
AdVAV Anthrax Vaccine - Drug Profile
Epicutaneous Anthrax Vaccines - Drug Profile
SMT-15000 - Drug Profile
Subunit Vaccine For Anthrax - Drug Profile
Monoclonal Antibody For Respiratory Anthrax - Drug Profile
Anthrax Vaccine - Drug Profile
Recombinant Protective Antigen Anthrax Vaccine - Drug Profile
TP-271 - Drug Profile
PolyMap - Drug Profile
Anthrax Capsule Vaccine - Drug Profile
Vaccine Adjuvant - Drug Profile
DPX-Anthrax Vaccine - Drug Profile
MU-1140-S - Drug Profile
Metalloproteinase Inhibitors - Drug Profile
Human Antibody Based Vaccines - Drug Profile
Subunit Vaccine For Anthrax-Plague Combination - Drug Profile
SGX-204 - Drug Profile
Anthrax Program - Drug Profile
GREANX - Drug Profile
ABNV-07 - Drug Profile
W1-mAb - Drug Profile
Epimerox - Drug Profile
Snare Antibacterial For Anthrax - Drug Profile
Next Generation Anthrax Vaccines - Drug Profile
KKL-35 - Drug Profile
Anthrax - Recent Pipeline Updates
Anthrax - Dormant Projects
Anthrax - Discontinued Products
Anthrax - Product Development Milestones
Featured News & Press Releases
For more information visit http://www.researchandmarkets.com/research/6tps3s/anthrax
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.